Literature DB >> 15067214

Chronic hypoxia- and monocrotaline-induced elevation of hypoxia-inducible factor-1 alpha levels and pulmonary hypertension.

Yih-Loong Lai1, Tai Chung Law.   

Abstract

A close relationship exists between hypoxia-inducible factor (HIF)-1alpha and pulmonary hypertension. The present study was carried out to explore if there are temporal alterations in HIF-1alpha levels during prolonged hypoxia and after monocrotaline (MCT) treatment. First, young Wistar rats were divided into 5 groups: control, hypoxia-1, hypoxia-2, hypoxia-3 and hypoxia-4. Hypoxic rats were placed in a closed hypobaric chamber (380 mm Hg) for a 1-week (hypoxia-1), 2-week (hypoxia-2), 3-week (hypoxia-3) or 5-week (hypoxia-4) period. Second, other young Wistar rats were divided into 4 groups: control, MCT-1, MCT-2 and MCT-3. MCT-treated rats were injected subcutaneously once with MCT (60 mg/kg) for a 1-week (MCT-1), 2-week (MCT-2) or 3-week (MCT-3) period. Subsequently, pulmonary arterial pressure (Ppa) and the weight ratio of the right ventricle to the left ventricle plus the septum [RV/(LV + S)] were measured, and lungs were obtained for the determination of HIF-1alpha via Western blot analysis. Both hypoxia and MCT induced temporal increases in the Ppa, the ratio RV/(LV + S) and HIF-1alpha levels. A close relationship between the Ppa and HIF-1alpha level was found in both hypoxia- and MCT-treated animals. In addition, the PaO(2) level significantly decreased in rats 1-3 weeks after MCT treatment. These results, along with previous data in the literature, suggest that both chronic hypoxia- and MCT-induced lung hypoxia activate an increase in the production of HIF-1alpha, and result in vascular remodeling and pulmonary hypertension. Copyright 2004 National Science Council, ROC and S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067214     DOI: 10.1007/bf02254435

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  7 in total

1.  MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach.

Authors:  Victoria N Parikh; Richard C Jin; Sabrina Rabello; Natali Gulbahce; Kevin White; Andrew Hale; Katherine A Cottrill; Rahamthulla S Shaik; Aaron B Waxman; Ying-Yi Zhang; Bradley A Maron; Jochen C Hartner; Yuko Fujiwara; Stuart H Orkin; Kathleen J Haley; Albert-László Barabási; Joseph Loscalzo; Stephen Y Chan
Journal:  Circulation       Date:  2012-02-27       Impact factor: 29.690

Review 2.  Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease.

Authors:  Stevan P Tofovic
Journal:  J Cardiovasc Pharmacol       Date:  2010-12       Impact factor: 3.105

3.  Genome-wide Meta-analysis Reveals New Gene Signatures and Potential Drug Targets of Hypertension.

Authors:  Fawad Ali; Arifullah Khan; Syed Aun Muhammad; Syed Qamar Abbas; Syed Shams Ul Hassan; Simona Bungau
Journal:  ACS Omega       Date:  2022-06-20

4.  Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency.

Authors:  Vivek Gupta; Nilesh Gupta; Imam H Shaik; Reza Mehvar; Eva Nozik-Grayck; Ivan F McMurtry; Masahiko Oka; Masanobu Komatsu; Fakhrul Ahsan
Journal:  Mol Pharm       Date:  2013-03-26       Impact factor: 4.939

5.  Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series).

Authors:  Michiel Alexander De Raaf; Aysar Al Hussaini; Jose Gomez-Arroyo; Donatas Kraskaukas; Daniela Farkas; Chris Happé; Norbert F Voelkel; Harm Jan Bogaard
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

6.  Protection of oral hydrogen water as an antioxidant on pulmonary hypertension.

Authors:  Bin He; Yufeng Zhang; Bo Kang; Jian Xiao; Bing Xie; Zhinong Wang
Journal:  Mol Biol Rep       Date:  2013-08-18       Impact factor: 2.316

Review 7.  Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension.

Authors:  Stevan P Tofovic; Edwin K Jackson
Journal:  Int J Mol Sci       Date:  2019-12-23       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.